Overview of Treatment-Emergent Adverse Events (Summary)
Study CDISCPILOT01 — Safety Analysis Set
	Placebo	Xanomeline Low Dose	Xanomeline High Dose	Total	
	(N=86)	(N=96)	(N=72)	(N=254)	
Adverse events					
Number of events	281	427	414	1122	
Subjects with ≥1 adverse event	65 (75.6%)	84 (87.5%)	68 (94.4%)	217 (85.4%)	
Subjects with a serious adverse event	0 (0.0%)	2 (2.1%)	1 (1.4%)	3 (1.2%)	
Subjects with a fatal adverse event	2 (2.3%)	1 (1.0%)	0 (0.0%)	3 (1.2%)	
Subjects with a related adverse event	43 (50.0%)	77 (80.2%)	64 (88.9%)	184 (72.4%)	
Subjects by severity, n (%)					
Mild	58 (67.4%)	64 (66.7%)	64 (88.9%)	186 (73.2%)	
Moderate	25 (29.1%)	58 (60.4%)	46 (63.9%)	129 (50.8%)	
Severe	5 (5.8%)	16 (16.7%)	8 (11.1%)	29 (11.4%)	
A treatment-emergent adverse event is an event with TRTEMFL = 'Y'.
Percentages are based on the number of subjects in the safety analysis set for each treatment group.
Subjects reporting more than one event are counted once in each row they qualify for; severity rows count subjects with at least one event of that severity and therefore do not sum to the number of subjects with any event.	
Source: adae, adsl (pharmaverseadam). Data cut-off: 2014-07-01. open.csr display t-ae-overview (in-text variant); generated from the committed ARD.